이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

고령 환자의 난소암 스크리닝(PLCO Screening Trial)

2026년 11월 17일 업데이트: National Cancer Institute (NCI)

전립선, 폐, 결장직장 및 난소(PLCO) 암 검진 시험

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVES:

I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer in women aged 55-74 at entry.

SECONDARY OBJECTIVES:

I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.

II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.

IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.

OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).

ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.

ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with ovarian cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.

Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

After completion of screening, participants are followed up for at least 13 years.

연구 유형

중재적

등록 (실제)

78216

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • National Institutes of Health Clinical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

55년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Exclusion Criteria:

  • Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age

  • Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer

  • Individuals with known prior cancer of the colon, rectum, lung, or ovary

    • This includes primary or metastatic PLCO cancers
  • Individuals with previous surgical removal of the entire colon or one lung

    • Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
  • Individuals who are participating in another cancer screening or cancer primary prevention trial

  • Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.

  • Individuals who are unwilling or unable to sign the informed consent form

  • Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 상영
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
간섭 없음: Control

Participants receive standard medical care. Participants complete a DHQ at baseline.

활성 비교기: Ovarian Screening

Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

Correlative studies

Undergo questionnaire assessments

Undergo TVU

다른 이름들:
  • 초음파
  • 2차원 그레이스케일 초음파 이미징
  • 2차원 초음파 이미징
  • 2D-US
  • 초음파 검사
  • 초음파, 의료
  • 우리를

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
기간: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
기간: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

2차 결과 측정

결과 측정
측정값 설명
기간
Deaths From All Causes
기간: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Death Rates From All Causes
기간: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
기간: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer diagnoses confirmed by medical record abstraction.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
기간: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
기간: One year from screening examination

Number of positive screens with complications

One year from screening examination
T0 (Baseline) CA-125 Screening Results
기간: T0 (at study entry)

Cancer Antigen 125 (CA-125) result.

T0 (at study entry)
T0 (Baseline) TVU Screening Results
기간: T0 (at study entry)

Transvaginal Ultrasound (TVU) result.

T0 (at study entry)
T1 CA-125 Screening Results
기간: T1 (one year after entry)

Cancer Antigen 125 (CA-125) result.

T1 (one year after entry)
T1 TVU Screening Results
기간: T1 (one year after entry)

Transvaginal Ultrasound (TVU) result.

T1 (one year after entry)
T2 CA-125 Screening Results
기간: T2 (two years after entry)

Cancer Antigen 125 (CA-125) result.

T2 (two years after entry)
T2 TVU Screening Results
기간: T2 (one year after entry)

Transvaginal Ultrasound (TVU) result.

T2 (one year after entry)
T3 CA-125 Screening Results
기간: T3 (three years after entry)

Cancer Antigen 125 (CA-125) result.

T3 (three years after entry)
T3 TVU Screening Results
기간: T3 (three years after entry)

Transvaginal Ultrasound (TVU) result.

T3 (three years after entry)
T4 CA-125 Screening Results
기간: T4 (four years after entry)

Cancer Antigen 125 (CA-125) result.

T4 (four years after entry)
T5 CA-125 Screening Results
기간: T5 (five years after entry)

Cancer Antigen 125 (CA-125) result.

T5 (five years after entry)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Christine D Berg, National Cancer Institute (NCI)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

1993년 11월 16일

기본 완료 (실제)

2012년 5월 21일

연구 완료 (추정된)

2027년 6월 30일

연구 등록 날짜

최초 제출

2012년 9월 28일

QC 기준을 충족하는 최초 제출

2012년 10월 1일

처음 게시됨 (추정된)

2012년 10월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 17일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NCI-2012-01758
  • CDR0000078532
  • NCI-P93-0050
  • PLCO-1
  • NCI-2012-01758 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • PLCO-Ovarian (기타 식별자: National Cancer Institute)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .